{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:55:37Z","timestamp":1791780937667,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40261-025-01501-3","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:07:43Z","timestamp":1764846463000},"page":"5-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review"],"prefix":"10.1007","volume":"46","author":[{"given":"Sophie","family":"Cooling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-0687","authenticated-orcid":false,"given":"Yvonne Ann","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1580","authenticated-orcid":false,"given":"David","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-4444","authenticated-orcid":false,"given":"Christine Mary","family":"Hallinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1501_CR1","doi-asserted-by":"crossref","unstructured":"Mollner, K., Global impacts of legalization and decriminalization of marijuana and cannabis. J Toxicol Risk Assess 2022;8(1).","DOI":"10.23937\/2572-4061.1510046"},{"key":"1501_CR2","unstructured":"Guidance for the use of medicinal cannabis in Australia: Overview. 2017 17\/06\/2024]. https:\/\/www.tga.gov.au\/resources\/resource\/guidance\/guidance-use-medicinal-cannabis-australia-overview. Accessed 17 June 2024."},{"issue":"3","key":"1501_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","volume":"14","author":"C Collin","year":"2007","unstructured":"Collin C, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290\u20136.","journal-title":"Eur J Neurol"},{"issue":"21","key":"1501_CR4","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med"},{"issue":"14","key":"1501_CR5","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204\u201311.","journal-title":"Neurology"},{"issue":"8","key":"1501_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia"},{"key":"1501_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jpsychires.2021.05.044","volume":"140","author":"KA McKee","year":"2021","unstructured":"McKee KA, et al. Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: a systematic review and meta-analysis of randomised controlled trials. J Psychiatr Res. 2021;140:267\u201381.","journal-title":"J Psychiatr Res"},{"key":"1501_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jpsychires.2020.07.030","volume":"129","author":"A Bahji","year":"2020","unstructured":"Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review & meta-analysis. J Psychiatr Res. 2020;129:257\u201364.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"1501_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42238-019-0012-y","volume":"2","author":"R Khan","year":"2020","unstructured":"Khan R, et al. The therapeutic role of cannabidiol in mental health: a systematic review. J Cannabis Res. 2020;2(1):2.","journal-title":"J Cannabis Res"},{"issue":"1","key":"1501_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","volume":"20","author":"J Sarris","year":"2020","unstructured":"Sarris J, et al. Medicinal cannabis for psychiatric disorders: a clinically focused systematic review. BMC Psychiatry. 2020;20(1):24.","journal-title":"BMC Psychiatry"},{"key":"1501_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso S, et al. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282\u201398.","journal-title":"Neurotoxicology"},{"issue":"1","key":"1501_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","volume":"269","author":"E Hoch","year":"2019","unstructured":"Hoch E, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):87\u2013105.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"24","key":"1501_CR13","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456\u201373.","journal-title":"JAMA"},{"issue":"12","key":"1501_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995\u20131010.","journal-title":"Lancet Psychiatry"},{"key":"1501_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.620073","author":"M Graczyk","year":"2021","unstructured":"Graczyk M, \u0141ukowicz M, Dzierzanowski T. Prospects for the use of cannabinoids in psychiatric disorders. Front Psychiatry. 2021. https:\/\/doi.org\/10.3389\/fpsyt.2021.620073.","journal-title":"Front Psychiatry"},{"issue":"4","key":"1501_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/appi.ps.202000189","volume":"72","author":"CN Stanciu","year":"2021","unstructured":"Stanciu CN, et al. Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv. 2021;72(4):429\u201336.","journal-title":"Psychiatr Serv"},{"key":"1501_CR17","doi-asserted-by":"publisher","first-page":"1142680","DOI":"10.3389\/fphar.2023.1142680","volume":"14","author":"EA Cairns","year":"2023","unstructured":"Cairns EA, et al. Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Front Pharmacol. 2023;14:1142680.","journal-title":"Front Pharmacol"},{"key":"1501_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171","author":"PB Burns","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011. https:\/\/doi.org\/10.1097\/PRS.0b013e318219c171.","journal-title":"Plast Reconstr Surg"},{"key":"1501_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0611-x","author":"Z Munn","year":"2018","unstructured":"Munn Z, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018. https:\/\/doi.org\/10.1186\/s12874-018-0611-x.","journal-title":"BMC Med Res Methodol"},{"key":"1501_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/pch\/pxaa031","volume":"26","author":"C Pawliuk","year":"2021","unstructured":"Pawliuk C, et al. Efficacy and safety of paediatric medicinal cannabis use: a scoping review. Paediatr Child Health. 2021;26:228\u201333.","journal-title":"Paediatr Child Health"},{"issue":"1","key":"1501_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/cch.12909","volume":"48","author":"S Fletcher","year":"2022","unstructured":"Fletcher S, et al. Medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review. Child Care Health Dev. 2022;48(1):33\u201344.","journal-title":"Child Care Health Dev"},{"issue":"7","key":"1501_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"1501_CR23","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Providence: American Psychiatric Association, American Psychiatric Publishing; 2022.","edition":"5"},{"key":"1501_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley AM, et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579.","journal-title":"BMC Health Serv Res"},{"key":"1501_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-030-52927-7_2","volume-title":"Regulating cannabis: a global review and future directions","author":"T Seddon","year":"2020","unstructured":"Seddon T, Floodgate W. A global review of cannabis regulation models. In: Seddon T, Floodgate W, editors. Regulating cannabis: a global review and future directions. Cham: Springer International Publishing; 2020. p. 15\u201383."},{"issue":"6","key":"1501_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinthera.2023.04.011","volume":"45","author":"JK Johnson","year":"2023","unstructured":"Johnson JK, Colby A. History of cannabis regulation and medicinal therapeutics: it\u2019s complicated. Clin Ther. 2023;45(6):521\u20136.","journal-title":"Clin Ther"},{"key":"1501_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2020.11.003","volume":"133","author":"J Thomas","year":"2021","unstructured":"Thomas J, et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. J Clin Epidemiol. 2021;133:140\u201351.","journal-title":"J Clin Epidemiol"},{"key":"1501_CR28","unstructured":"Covidence Systematic Review Software. n.d. https:\/\/www.covidence.org\/. Accessed 17 June 2024."},{"key":"1501_CR29","unstructured":"CASP Randomised Controlled Trial Standard Checklist. 2018. https:\/\/casp-uk.net\/checklists\/casp-rct-randomised-controlled-trial-checklist.pdf. Accessed 17 June 2024."},{"issue":"8","key":"1501_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, et al. Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795\u2013808.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1501_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1501_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121\u201330.","journal-title":"J Psychopharmacol"},{"key":"1501_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","volume":"59","author":"CM Kwee","year":"2022","unstructured":"Kwee CM, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. Eur Neuropsychopharmacol. 2022;59:58\u201367.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1501_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-021-00420-2","author":"A Aran","year":"2021","unstructured":"Aran A, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021. https:\/\/doi.org\/10.1186\/s13229-021-00420-2.","journal-title":"Mol Autism"},{"key":"1501_CR35","unstructured":"da Silva EA Jr, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends Psychiatry Psychother. 2024;46."},{"issue":"4","key":"1501_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/07067437231209650","volume":"69","author":"JV Pinto","year":"2024","unstructured":"Pinto JV, et al. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study. Can J Psychiatry-Rev Can Psychiatr. 2024;69(4):242\u201351.","journal-title":"Can J Psychiatry-Rev Can Psychiatr"},{"issue":"3","key":"1501_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","volume":"71","author":"DJ Allsop","year":"2014","unstructured":"Allsop DJ, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal a randomized clinical trial. JAMA Psychiatr. 2014;71(3):281\u201391.","journal-title":"JAMA Psychiatr"},{"key":"1501_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","volume":"161","author":"JM Trigo","year":"2016","unstructured":"Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016;161:298\u2013306. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.02.020.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1501_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190768","volume":"13","author":"JM Trigo","year":"2018","unstructured":"Trigo JM, et al. Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS ONE. 2018;13(1):e0190768.","journal-title":"PLoS ONE"},{"issue":"10","key":"1501_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7(10):865\u201374.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"1501_CR41","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/add.15417","volume":"116","author":"V Mongeau-P\u00e9russe","year":"2021","unstructured":"Mongeau-P\u00e9russe V, et al. Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction. 2021;116(9):2431\u201342.","journal-title":"Addiction"},{"issue":"5","key":"1501_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","volume":"43","author":"C de Meneses-Gaya","year":"2021","unstructured":"de Meneses-Gaya C, et al. Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Braz J Psychiatry. 2021;43(5):467\u201376.","journal-title":"Braz J Psychiatry"},{"issue":"5","key":"1501_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/ADM.0000000000000959","volume":"16","author":"V Mongeau-P\u00e9russe","year":"2022","unstructured":"Mongeau-P\u00e9russe V, et al. Cannabidiol effect on anxiety symptoms and stress response in individuals with cocaine use disorder: exploratory results from a randomized controlled trial. J Addict Med. 2022;16(5):521\u20136.","journal-title":"J Addict Med"},{"key":"1501_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-024-01287-z","author":"AD Gallassi","year":"2024","unstructured":"Gallassi AD, et al. Cannabidiol compared to pharmacological treatment as usual for crack use disorder: a feasibility, preliminary efficacy, parallel, double-blind, randomized clinical trial. Int J Ment Health Addict. 2024. https:\/\/doi.org\/10.1007\/s11469-024-01287-z.","journal-title":"Int J Ment Health Addict"},{"issue":"8","key":"1501_CR45","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/da.23032","volume":"37","author":"RR Kayser","year":"2020","unstructured":"Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: a human laboratory study. Depress Anxiety. 2020;37(8):801\u201311. https:\/\/doi.org\/10.1002\/da.23032.","journal-title":"Depress Anxiety"},{"issue":"11","key":"1501_CR46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911\u201322.","journal-title":"Am J Psychiatry"},{"key":"1501_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1155984","author":"J Suzuki","year":"2023","unstructured":"Suzuki J, et al. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: a pilot, double-blind, placebo-controlled, randomized cross-over trial. Front Psychiatry. 2023. https:\/\/doi.org\/10.3389\/fpsyt.2023.1155984.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1501_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246990","volume":"16","author":"MO Bonn-Miller","year":"2021","unstructured":"Bonn-Miller MO, Sisley S, Riggs P, Yazar-Klosinski B, Wang JB, Loflin MJE, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS ONE. 2021;16(3):e0246990. https:\/\/doi.org\/10.1371\/journal.pone.0246990.","journal-title":"PLoS ONE"},{"issue":"5","key":"1501_CR49","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","volume":"239","author":"LM Bolsoni","year":"2022","unstructured":"Bolsoni LM, et al. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology. 2022;239(5):1499\u2013507.","journal-title":"Psychopharmacology"},{"key":"1501_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07543-2","author":"Z Walsh","year":"2023","unstructured":"Walsh Z, et al. A small clinical trial of vaporized cannabis for PTSD: suggestive results and directions for future study. Trials. 2023. https:\/\/doi.org\/10.1186\/s13063-023-07543-2.","journal-title":"Trials"},{"issue":"6","key":"1501_CR51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D\u2019Souza","year":"2005","unstructured":"D\u2019Souza DC, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594\u2013608.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1501_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"1501_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"1501_CR54","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo-controlled trial. Psychopharmacology. 2018;235(7):1923\u201332.","journal-title":"Psychopharmacology"},{"key":"1501_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.614811","author":"FM Leweke","year":"2021","unstructured":"Leweke FM, et al. Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.614811.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1501_CR56","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38(9):2433\u20136.","journal-title":"Addict Behav"},{"key":"1501_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115135","volume":"323","author":"KR M\u00fcller-Vahl","year":"2023","unstructured":"M\u00fcller-Vahl KR, Pisarenko A, Szejko N, Haas M, Fremer C, Jakubovski E, et al. CANNA-TICS: efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders\u2014results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Psychiatry Res. 2023;323:115135. https:\/\/doi.org\/10.1016\/j.psychres.2023.115135.","journal-title":"Psychiatry Res"},{"issue":"1","key":"1501_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42238-022-00142-z","volume":"4","author":"MR de Souza","year":"2022","unstructured":"de Souza MR, Henriques AT, Limberger RP. Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario. J Cannabis Res. 2022;4(1):33.","journal-title":"J Cannabis Res"},{"issue":"1","key":"1501_CR59","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13034-024-00846-5","volume":"18","author":"P K\u00f6ck","year":"2024","unstructured":"K\u00f6ck P, et al. Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials. Child Adolesc Psychiatry Ment Health. 2024;18(1):158.","journal-title":"Child Adolesc Psychiatry Ment Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01501-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01501-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01501-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:03:10Z","timestamp":1768838590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01501-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01501-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SC, YB, and CMH designed the review and drafted the initial manuscript. SC, YB and CMH contributed to the abstract, screening, and data extraction for the included studies. SC, YB and CMH provided critical review of the included studies and interpretation of the result. All authors SC, YB, DC and CMH contributed to manuscript development. SC and CMH prepared the manuscript for submission. CMH undertook the major revision of the manuscript, with input from all authors. All authors approved manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}